Product Pathways - Adhesion
Lyric/Metadherin (2F11C3) Mouse mAb #9596
|9596S||100 µl (10 western blots)||---||In Stock||---|
|9596||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Monkey||Endogenous||65, 75||Mouse IgG1|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Specificity / Sensitivity
Lyric/Metadherin (2F11C3) Mouse mAb detects endogenous levels of total lyric/metadherin protein.
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human lyric/metadherin protein.
Lyric/AEG-1 (Astrocyte Elevated Gene 1)/MTDH (Metadherin) was identified as a tight junction (TJ) protein based on its localization to TJ proteins in polarized epithelium (1).
Differential subcellular localization and overexpression of Lyric/AEG-1/MTDH has been seen in multiple human cancers. Lyric/AEG-1/MTDH is involved in signaling pathways related to various cellular functions including proliferation and apoptosis/survival, and its alteration in cancer is associated with poor prognosis (reviewed in 2). In breast cancer, increased Lyric/AEG-1/MTDH may confer increased chemoresistance as well as metastasis (3,4). Lyric/AEG-1/MTDH expression is important in signaling and disease progression of hepatocellular carcinoma (HCC) (5) and glioblastoma multiforme (GBM) (6).
- Britt, D.E. et al. (2004) Exp Cell Res 300, 134-48.
- Hu, G. et al. (2009) Clin Cancer Res 15, 5615-20.
- Brown, D.M. and Ruoslahti, E. (2004) Cancer Cell 5, 365-74.
- Hu, G. et al. (2009) Cancer Cell 15, 9-20.
- Yoo, B.K. et al. (2009) J Clin Invest 119, 465-77.
- Emdad, L. et al. (2010) Mol Cancer Ther 9, 79-88.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.